天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (5): 548-551.doi: 10.11958/20150286

• 专题研究-消化疾病 • 上一篇    下一篇

胃癌组织中干细胞标志物 Sox2 的表达及临床意义

陈忠 1， 谢峰 2， 钟丰云 3， 杜鸿 4， 严永敏 5， 钱晖 5   

  1. 1苏州永鼎医院检验科（邮编 215200）， 2普通外科； 3苏州大学附属第二医院普通外科， 4检验科； 5江苏大学医学院， 江苏省检 验医学重点实验室
  • 收稿日期:2015-11-05 修回日期:2016-01-09 出版日期:2016-05-15 发布日期:2016-05-18
  • 通讯作者: 陈忠 E-mail:cz6766@sina.com
  • 作者简介:陈忠 （1968）， 男， 副主任技师， 硕士， 主要从事血液及肿瘤分子生物学诊断研究
  • 基金资助:
    苏州市科技发展计划项目 （SYSD2012048）

Expression and clinical significance of stem cell marker Sox2 in human gastric cancer

CHEN Zhong1, XIE Feng2, ZHONG Fengyun3, DU Hong4, YAN Yongmin5, QIAN Hui5   

  1. 1 Clinical Laboratory, 2 General Surgery, Suzhou Yongding Hospital, Suzhou 215200, China; 3 General Surgery, 4 Clinical Laboratory, the 2nd Affiliated Hospital of Soochow University; 5 School of Medicine, Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Jiangsu University
  • Received:2015-11-05 Revised:2016-01-09 Published:2016-05-15 Online:2016-05-18
  • Contact: Zhong CHEN E-mail:cz6766@sina.com

PDF (PC)

4420

摘要： 摘要： 目的 探讨胃癌组织中干细胞标志物 Sox2 的表达及临床意义。方法 RT-PCR 检测 60 例胃癌患者癌组 织（胃癌组）和癌旁组织（癌旁组）中 Sox2 mRNA 表达， 免疫组织化学法检测 2 组 Sox2 蛋白表达水平。比较 Sox2 mRNA 阳性表达情况在不同年龄、 性别、 肿瘤大小、 组织类型、 TNM 分期、 分化程度、 浸润深度及淋巴结转移中的差 异。结果 胃癌组 Sox2 mRNA 阳性表达率 53.3% （32/60） 高于癌旁组的 20.0%（12/60）； Sox2 mRNA 的相对表达强度 高于癌旁组（0.724±0.209 vs. 0.256±0.065， P＜0.01）。胃癌组 Sox2 蛋白的阳性表达率 50.0%（30/60）高于癌旁组的 16.7%（10/60， P＜0.01）。胃癌组 Sox2 mRNA 阳性表达率临床 TNM 分期（Ⅲ＋Ⅳ）组高于（Ⅰ＋Ⅱ）组， 低、 未分化组 高于中、 高分化组， 浸润深度 T3～T4组高于 T1～T2组， 淋巴结转移组高于无转移组（均 P＜0.05 或 P＜0.01）。结论 胃癌组织中 Sox2 高表达与其发生、 侵袭、 进展及转移有关， 可作为胃癌诊疗新的分子标志物。

关键词: 胃肿瘤, 肿瘤干细胞, 基因, 肿瘤抑制, 免疫组织化学, 逆转录聚合酶链反应, 干细胞标志物 Sox2

Abstract: Abstract： Objective To detect the expression of stem cell marker Sox2 in gastric cancer (GC). Methods The mRNA and protein expressions of Sox2 in paired primary tumor tissues and their matching, adjacent non-cancerous tissues in a series of 60 cases of human GC were examined by reverse transcription-PCR (RT-PCR) and immunohistochemistry (IHC). χ2 test was used to analyze the correlation of Sox2 expression with clinicopathological parameters of GC tissues including age, gender, tumor size, histological type, TNM stage, differentiation degree, depth of invasion and lymph node metastasis. Results RT-PCR results showed that the positive rate of Sox2 expression was significantly increased in gastric tumor tissues (53.3%, 32/60) compared with that of matching, adjacent non-cancerous tissues (20.0%, 12/60, P＜0.01). Semi-quantitative analysis showed that the relative intensity of Sox2 mRNA expression was significantly higher in gastric cancer tissues (0.724±0.209) than that in tissues adjacent to carcinoma (0.256±0.065， P＜0.01). The positive expression of Sox2 was significantly higher in gastric tumor tissues (50.0%, 30/60) than that of matching, adjacent non-cancerous tissues (16.7%, 10/60， P＜0.01). The positive expression of Sox2 was significantly higher in gastric tumor patients with TNM stage (Ⅲ＋Ⅳ) than that of TNM stage (Ⅰ＋Ⅱ). The positive expression of Sox2 was significantly higher in gastric tumor patients with low differentiation and undifferentiated tumor cells than that of patients with middle and high differented cells. The positive expression of Sox2 was also significantly higher in gastric tumor patients with the depth of invasion T3-T4 than that of patients with T1- T2. The positive expression of Sox2 was significantly higher in gastric tumor patients with lymph node metastasis than that of patients without lymph node metastasis (P＜0.05 or P＜0.01). Conclusion The elevated expression of Sox2 is associated with the initiation, invasion, progression, and metastasis of GC. Sox2 may serve as a novel diagnostic and therapeutic marker for human GC.

Key words: stomach neoplasms, neoplastic stem cells, genes, tumor suppressor, immunohistochemistry, reverse tran? scriptase polymerase chain reaction, SRY-related HMG-box gene 2